Caligan Partners LP - Significant Ownership

Signature - Title
/s/ David Johnson - David Johnson, Managing Partner
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Caligan Partners LP.

Significant Ownership of Caligan Partners LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VRCA Verrica Pharmaceuticals Inc. Common Stock, par value $0.0001 per share 9.99% $23M 6.5M Caligan Partners LP Nov 23, 2025
VRCA Verrica Pharmaceuticals Inc. Common stock, $0.0001 par value per share 9.99% $7.61M 15.9M Caligan Partners LP Dec 31, 2024
ANIK Anika Therapeutics, Inc. Common Stock, par value $0.01 per share 9.95% $14.4M 1.44M Caligan Partners LP Nov 19, 2025
EOLS Evolus, Inc. Common Stock, par value $0.00001 per share 6.4% $25.4M $4.89M 4.14M +23.8% Caligan Partners LP Sep 30, 2025
AVTX Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share 6.3% $10.6M 833K Caligan Partners LP Sep 30, 2025
YMAB Y-mAbs Therapeutics, Inc. Common stock, par value $0.0001 per share 0% $0 -$20.2M 0 -100% Caligan Partners LP Sep 30, 2025

Schedules 13D/G Reported by Caligan Partners LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.